ReviewVascular health and risk management2009
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.
Review in Vascular health and risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01195818 (Effect of RAS Inhibitors on Albuminuria, Hyperfiltration and Endothelial Dysfunction in a Sickle Cell Disease Population.), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of RAS Inhibitors on Albuminuria, Hyperfiltration and Endothelial Dysfunction in a Sickle Cell Disease Population.
Who cites it
17 citing papers in PubMed, 51 citations in OpenAlex.
- Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.Journal of clinical hypertension (Greenwich, Conn.) · 2011Trial
- The role of single-pill ACE inhibitor/ccb combination for hypertension: an Algerian view via the nominal group technique.Future cardiology · 2025Review
- mRNA Metabolism and Hypertension.Biomedicines · 2023Review
- Blood pressure control in hypertensive patients attending a rural community health centre in Gauteng Province, South Africa: A cross-sectional study.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2022Article
- Advances in the Treatment Strategies in Hypertension: Present and Future.Journal of cardiovascular development and disease · 2022Review
- Cell Death Pathways in Mutant Rhodopsin Rat Models Identifies Genotype-Specific Targets Controlling Retinal Degeneration.Molecular neurobiology · 2019Article
- Recommended treatment protocols to improve management of hypertension globally: A statement by Resolve to Save Lives and the World Hypertension League (WHL).Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Enhanced hemodynamic responses to angiotensin II in diabetes are associated with increased expression and activity of AT1 receptors in the afferent arteriole.Physiological genomics · 2017Article
- Blood pressure control in type 2 diabetic patients.Cardiovascular diabetology · 2017Review
- Correlation between Diastolic Function and Endothelial Function in Patients with Type 2 Diabetes and Hypertension.The open cardiovascular medicine journal · 2016Article
- Emerging drug combinations to optimize renovascular protection and blood pressure goals.International journal of nephrology and renovascular disease · 2012Article
- Optimal therapy in hypertensive subjects with diabetes mellitus.Current atherosclerosis reports · 2011Review
- The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.Cardiovascular diabetology · 2010Article
- Optimizing blood pressure control in patients with chronic kidney disease.Proceedings (Baylor University. Medical Center) · 2010Article
- Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient.Therapeutic advances in endocrinology and metabolism · 2010Article
- Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.Clinical drug investigation · 2010Review
- Efficacy and Tolerability of Antihypertensive Drugs in Diabetic and Nondiabetic Patients.Journal of pharmacy & bioallied sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diabetes epidemic continues to grow unabated, with a staggering toll in micro- and macrovascular complications, disability, and death. Diabetes causes a two- to fourfold increase in the risk of cardiovascular disease, and represents the first cause of dialysis treatment both in the UK and the US. Concomitant hypertension doubles total mortality and stroke risk, triples the risk of coronary heart disease and significantly hastens the progression of microvascular complications, including diabetic nephropathy. Therefore, blood pressure reduction is of particular importance in preventing cardiovascular and renal outcomes. Successful antihypertensive treatment will often require a combination therapy, either with separate drugs or with fixed-dose combinations. Angiotensin converting enzyme (ACE) inhibitor plus diuretic combination therapy improves blood pressure control, counterbalances renin-angiotensin system activation due to diuretic therapy and reduces the risk of electrolyte alterations, obtaining at the same time synergistic antiproteinuric effects. ACE inhibitor plus calcium channel blocker provides a significant additive effect on blood pressure reduction, may have favorable metabolic effects and synergistically reduce proteinuria and the rate of decline in glomerular filtration rate, as evidenced by the GUARD trial. Finally, the recently published ACCOMPLISH trial showed that an ACE inhibitor/calcium channel blocker combination may be particularly useful in reducing cardiovascular outcomes in high-risk patients. The present review will focus on different ACE inhibitor combinations in the treatment of patients with type 2 diabetes mellitus and hypertension, in the light of recent clinical trials, including GUARD and ACCOMPLISH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.